Company Overview - Yangmei Biotechnology (Chengdu) Co., Ltd. is a medical health enterprise established in 2016, focusing on the research, production, and commercialization of regenerative medical devices and special medical foods [3] - The company specializes in the development, transformation, and application of regenerative medical materials, as well as the research and development of specific full-nutrition formula foods [3] - Yangmei Biotechnology has accumulated key technologies in the fields of polymer materials and regenerative biomaterials, including research, modification, preparation, and the development of microspheres [3] Product Lines - The company has a strong product portfolio that includes two main product lines: regenerative medical material injectables and medical dressings and patches [3] - As of May 5, 2025, the company has 13 candidate products for regenerative medical material injectables, including core product XH301 and candidate product XH321 for treating female stress urinary incontinence, with two products already in the registration review stage [4] - In the medical dressings and patches product line, seven products have obtained second-class medical device registration approval, and one candidate product XH322 for breast reconstruction post-breast cancer surgery is in the preclinical stage [4] - The special medical food product line includes two products approved by the National Medical Products Administration and seven candidate products under development [4] Financial Performance - The company's revenue for 2023 and 2024 is projected to be RMB 12.88 million and RMB 14.52 million, respectively [5] - The total loss for the same periods is expected to be RMB 63.50 million and RMB 69.38 million, indicating ongoing financial challenges [5] - Gross profit for 2023 is RMB 1.47 million, which decreases to RMB 0.38 million in 2024, reflecting a decline in profitability [5]
新股消息 | 妍美生物递表港交所 拥有13款主要再生医学材料注射剂候选产品
智通财经网·2025-05-12 22:57